{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:47:40Z","timestamp":1773020860119,"version":"3.50.1"},"reference-count":14,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Hidradenitis suppurativa is a chronic, inflammatory, burdensome skin disease where current first-line treatments are limited to topical and\/or systemic antibiotics which cannot be applied for long-term disease management. Period B of the RELIEVE study analyzes whether LAight\u00ae therapy can sustain or even increase remission after a first topical antibiotic treatment cycle. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; The RELIEVE study was performed as a two-period multicenter randomized controlled trial with blinded assessment. For period A from week 0 to week 16, the 88 participating Hurley I and II patients were randomized to either a group receiving topical clindamycin 1% solution combined with 8 additional bi-weekly treatments with LAight\u00ae therapy (group TC + L) or a group which was treated with topical clindamycin 1% solution only (group TC). After 16 weeks, patients entered open-label period B and both groups were treated exclusively with LAight\u00ae therapy for an additional 16 weeks (8 sessions, group TC + L\/L and group TC\/L). &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; In total, 88 patients were enrolled in RELIEVE. Seventy-eight patients entered period B; 39 belonged to group TC + L\/L and 39 to group TC\/L. The IHS4-response at the start of period B was 62% (group TC + L\/L) and 33% (group TC + L). During the 16 weeks of additional monotherapy with LAight, in both groups &amp;#x3e;90% of patients who responded to therapy in period A maintained their IHS4-response at week 32. IHS4 response rates continued to rise up to 79% of the TC + L\/L group and up to 71% of the TC\/L group during period B at week 32. Achievement of HiSCR and certain patient reported outcomes confirmed primary endpoint results. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; LAight\u00ae therapy is an effective approved therapy option for Hurley I and II HS that can be used continuously to maintain treatment success. During 16 weeks of follow-up in period B, over 90% of patients with response after period A maintained their treatment outcome, while more than 60% of prior nonresponders gained response. The fact that LAight\u00ae therapy can be applied continuously, is very effective and is well tolerated makes it a valuable treatment tool in the design of HS long-term treatment modalities. <\/jats:p>","DOI":"10.1159\/000524739","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T21:00:43Z","timestamp":1654808443000},"page":"1092-1103","source":"Crossref","is-referenced-by-count":12,"title":["LAight\u00ae Therapy Is an Effective Treatment Option to Maintain Long-Term Remission of Hurley I and II Hidradenitis Suppurativa: Results from Period B of RELIEVE, a Multicenter Randomized, Controlled Trial"],"prefix":"10.1159","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-074X","authenticated-orcid":false,"given":"Michael","family":"Schultheis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Staubach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ruckes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-9642","authenticated-orcid":false,"given":"Esther","family":"von Stebut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-6987","authenticated-orcid":false,"given":"Uwe","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2067-4929","authenticated-orcid":false,"given":"\u0141ukasz","family":"Matusiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Nikolakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9328-5"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000002671"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(98)70272-5"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.001"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4065\/84.11.979"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410017284"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15163"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08832.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20543"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000507323"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17265"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15500"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/14764172.2011.564626"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/524739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/524739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:56:23Z","timestamp":1745420183000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000524739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,3]]},"published-print":{"date-parts":[[2022,11,7]]}},"URL":"https:\/\/doi.org\/10.1159\/000524739","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}